Our pipeline
Prescient has a broad pipeline of later stage and emerging assets in next generation targeted and cellular therapies and spanning a range of different cancers.
Prescient has licensed technologies from and collaborates with world-leading cancer centres in the US and Australia.
Our technologies
Targeted therapy: PTX-100
PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. PTX-100 is now in a Phase 2a clinical study in refractory/relapsed Cutaneous T Cell Lymphoma. The US FDA has granted PTX-100 Orphan Drug Designation for all T cell lymphomas, Investigational New Drug (IND) status and Fast Track Designation.
Cell therapy: CellPryme
CellPryme is a high-performance cell therapy enhancement platform that can improve CAR-T efficacy. The CellPryme platform consists of two distinct components which can be used separately but have significant synergies when used together. CellPryme-M can be briefly added to standard manufacturing processes. CellPryme-A is used as an adjuvant alongside cellular immunotherapy.
Cell therapy: OmniCAR
The OmniCAR platform seeks to overcome the challenges of conventional CAR-T therapy including manufacturing, safety and reliability. OmniCAR is a modular, universal CAR platform based on technology licensed from UPenn and Oxford University. It allows unprecedented control and flexibility over current generation CAR-T approaches
Expanded Access Program
Prescient Therapeutics is committed to developing our targeted and cell therapies ethically, always keeping our patients’ safety at the forefront. Our goal is to ensure access to our investigational therapies that is clinically appropriate for patients. Currently, our compounds are still being tested in clinical trials and is not yet available on the market.
Prescient Therapeutics’ Expanded Access Policy refers to the use of our investigational targeted therapy (PTX-100) outside of a clinical trial. We recognise and understand the need for patients who have limited treatment options for their cancer to sometimes seek early access to investigational therapies that are still in clinical trials. This is different to a clinical trial setting where more comprehensive safety and efficacy data are collected.
The decision to establish an Expanded Access program is dependent on several factors that comply with the US Food and Drug Administration (FDA) and other regulatory agencies’ guidelines. These may include but are not limited to the following:
- The illness for which the investigational targeted therapy is being considered must be serious or life threatening, and for which there are no other suitable treatment options such as a marketed product or a clinical trial.
- There is sufficient evidence that the potential benefit of the investigational target therapy outweighs the potential risks, based on all available information.
- Providing the investigational target therapy will not interfere with the ongoing clinical trials.
Based on these factors, Prescient Therapeutics believes that participation in one of our clinical trials is the only clinically appropriate way to access our investigational targeted therapy. We do not currently provide PTX-100 through an Expanded Access program.
If you are a patient who is interested in our investigational targeted therapy, you can learn more about our ongoing clinical trials by going to www.clinicaltrials.gov and search for Prescient Therapeutics.
If you are a physician who is interested in learning more about our investigational targeted therapy, please contact the Chief Medical Officer at [email protected].